Fibroelastoma of Heart Valves

Introduction

When patients are told they have a tumour in their heart, it is entirely natural to feel a profound sense of anxiety. However, it is crucial to understand that the vast majority of primary cardiac tumours are benign, meaning they are not cancerous. Among these, the papillary fibroelastoma is the most common tumour to affect the heart valves [1] [2]. While the word “tumour” sounds alarming, a fibroelastoma is a slow-growing, non-cancerous growth. Nevertheless, because of its location on the delicate structures of the heart valves, it requires careful evaluation and, in many cases, surgical intervention to prevent serious complications.

In this comprehensive guide, I will explain what a papillary fibroelastoma is, explore its underlying causes, detail the symptoms it may produce, and discuss the clear indications for treatment. Most importantly, I will outline the modern surgical options available to patients today, with a particular focus on the significant benefits of minimally invasive keyhole heart surgery.

What is a Papillary Fibroelastoma?

A papillary fibroelastoma is a benign primary cardiac tumour. “Primary” means that the tumour originated within the heart itself, rather than spreading from another part of the body. Although primary heart tumours are exceedingly rare—affecting less than 0.1% of the population—papillary fibroelastomas are among the most frequently encountered types, alongside cardiac myxomas [1] [3].

These tumours have a very distinct appearance. Under a microscope or on an echocardiogram, a papillary fibroelastoma often resembles a small sea anemone [1] [3]. It typically consists of a central stalk attached to the endocardium (the inner lining of the heart), from which multiple tiny, frond-like arms project outward into the bloodstream [1].

In approximately 80% of cases, these tumours develop on the heart valves [3]. The aortic valve is the most commonly affected site, followed closely by the mitral valve [1] [3]. These valves are located on the left side of the heart, which pumps oxygen-rich blood to the rest of the body. Less frequently, fibroelastomas can be found on the tricuspid or pulmonary valves on the right side of the heart [3].

Unlike some other cardiac masses, papillary fibroelastomas are usually small—often measuring less than one centimetre in diameter—and they rarely interfere with the mechanical opening and closing of the heart valve itself [1] [3]. The primary danger they pose is not mechanical obstruction, but rather their potential to cause embolic events.

The Causes of Papillary Fibroelastoma

The precise aetiology, or cause, of papillary fibroelastomas remains a subject of ongoing medical research. Because these tumours are rare, large-scale studies pinpointing a single definitive cause are challenging to conduct. However, the prevailing scientific consensus suggests that they are not true neoplasms (cancers driven by genetic mutations) but rather reactive lesions that develop in response to localized tissue damage [1] [3].

Endothelial Damage and Microthrombi

The most widely accepted theory is that papillary fibroelastomas begin as tiny blood clots, known as microthrombi, that form at sites of minor damage to the endothelium (the delicate cellular lining of the heart valves) [1] [3].

The heart valves are subjected to immense mechanical stress. They open and close roughly 100,000 times a day, constantly bathed in high-pressure blood flow. Over time, this sheer mechanical force can cause microscopic wear and tear on the valve surface. When the endothelium is damaged, the body’s natural healing response is triggered, leading to the deposition of fibrin and the formation of small clots [1].

In most cases, these microthrombi are dissolved by the body. However, in the case of a fibroelastoma, it is believed that these clots persist and gradually organize. Over time, they become infiltrated by connective tissue cells, evolving into the characteristic frond-like structures composed of collagen, elastin, and a central core of mucopolysaccharides [1].

Associated Risk Factors

While anyone can develop a papillary fibroelastoma, certain factors that increase the likelihood of endothelial damage may elevate the risk. These include:

• Prior Cardiac Surgery: Previous interventions on the heart valves or endocardium can leave microscopic scars that serve as a nidus for tumour formation [4].
• Rheumatic Heart Disease: Conditions that cause chronic inflammation and scarring of the heart valves, such as rheumatic fever, create an environment conducive to the development of these lesions [4].
• Thoracic Radiation: Patients who have received radiation therapy to the chest for conditions such as breast cancer or lymphoma may experience long-term changes to the cardiac endothelium, increasing their risk [4].
• Age: Papillary fibroelastomas are most commonly diagnosed in adults in their 60s, reflecting the cumulative effect of mechanical wear and tear on the heart valves over a lifetime [1] [3].

Symptoms and Clinical Presentation

One of the most challenging aspects of managing papillary fibroelastomas is that the majority of patients are entirely asymptomatic [1] [3]. Because the tumours are small and typically do not impede valve function, they do not cause the classic signs of heart failure, such as severe breathlessness or fluid retention.

In many cases, a fibroelastoma is discovered incidentally. A patient may undergo an echocardiogram (an ultrasound of the heart) for an unrelated reason—such as a routine check-up, an evaluation for a heart murmur, or prior to a non-cardiac surgery—and the tumour is spotted by chance [1] [3].

The Risk of Embolisation

When symptoms do occur, they are almost always the result of embolisation [1] [3]. Embolisation happens when a piece of the tumour breaks off, or when a blood clot that has formed on the surface of the tumour dislodges and travels through the bloodstream. Because the majority of fibroelastomas are located on the left side of the heart (the aortic and mitral valves), any embolic material will be pumped directly into the systemic circulation. Depending on where the embolus travels, the consequences can be severe and potentially life-threatening:

• Cerebral Embolism (Stroke or TIA): If the embolus travels to the brain, it can block a cerebral artery, causing a stroke or a transient ischaemic attack (TIA, often called a “mini-stroke”). Stroke is the most common clinical presentation in symptomatic patients, occurring in up to 30% of those who develop symptoms [1] [3].
• Coronary Embolism (Heart Attack): If the embolus enters the coronary arteries, which supply blood to the heart muscle itself, it can cause angina (chest pain) or a myocardial infarction (heart attack) [1] [3].
• Other Systemic Emboli: Emboli can also travel to the kidneys, the mesenteric arteries (supplying the intestines), or the arteries of the legs, causing acute ischaemia and tissue damage in those areas [3].

In rare instances, a highly mobile tumour on the aortic valve may temporarily occlude the opening of a coronary artery during the cardiac cycle, leading to sudden, severe chest pain or even sudden cardiac death [1] [3].

Diagnosis of Papillary Fibroelastoma

The cornerstone of diagnosing a papillary fibroelastoma is echocardiography.

• Transthoracic Echocardiogram (TTE): This is the standard, non-invasive ultrasound performed on the outside of the chest. It is often the first test used and can detect larger tumours [1] [3].
• Transoesophageal Echocardiogram (TEE): If a TTE is inconclusive, or if a patient has suffered a stroke of unknown origin, a TEE is highly recommended. In this procedure, a specialized ultrasound probe is passed down the oesophagus, placing it directly behind the heart. This provides exceptionally clear, high-resolution images of the heart valves and is highly sensitive for detecting even very small fibroelastomas (less than 2 millimetres) [1] [3].

On an echocardiogram, a fibroelastoma typically appears as a small, mobile, speckled mass attached to the valve by a stalk, exhibiting independent motion as the heart beats [1] [3].

While advanced imaging modalities like Cardiac MRI or CT scans can provide additional spatial resolution, echocardiography remains the gold standard for initial diagnosis and surgical planning [1]. Definitive confirmation of the tumour type is only achieved through histological examination by a pathologist after the mass has been surgically removed [1].

Indications for Treatment: When is Surgery Necessary?

The decision to treat a papillary fibroelastoma requires a careful assessment of the patient’s individual risk profile. Because these tumours are benign, the goal of treatment is not to cure cancer, but to prevent the devastating complications of embolisation.

The medical community has established clear guidelines regarding the indications for surgical intervention:

Symptomatic Patients

There is universal consensus that any patient who has experienced symptoms related to a papillary fibroelastoma—such as a stroke, TIA, heart attack, or unexplained angina—should undergo prompt surgical excision [1] [5]. In these cases, the tumour has already demonstrated its potential to cause harm, and the risk of a recurrent, potentially fatal embolic event is unacceptably high. Surgery is the only definitive way to eliminate this risk.

Asymptomatic Patients

The management of asymptomatic patients is more nuanced and requires a detailed discussion between the patient and their cardiac surgeon. However, surgical excision is strongly recommended for asymptomatic patients if the tumour exhibits certain high-risk characteristics:

• Size: Tumours larger than 1 centimetre (10 millimetres) are generally considered for removal due to a higher theoretical risk of embolisation [1] [5].
• Mobility: A tumour that is highly mobile—meaning it swings freely on a stalk—is significantly more likely to break off or shed clots than a tumour that is firmly attached and immobile [1] [5]. Highly mobile tumours are a strong indication for surgery.
• Location: Tumours located on the left side of the heart (aortic or mitral valves) pose a much greater risk of causing a stroke or heart attack if they embolise, compared to right-sided tumours, which would embolise to the lungs. Therefore, left-sided lesions are treated more aggressively [5]

If an asymptomatic patient is undergoing cardiac surgery for another reason (for example, a coronary artery bypass or the repair of a different valve), any incidentally discovered fibroelastoma should be excised during the same operation [5].

The Role of Watchful Waiting and Anticoagulation

For asymptomatic patients with very small, non-mobile tumours, or for patients whose advanced age or severe co-morbidities make them poor candidates for surgery, a strategy of “watchful waiting” may be adopted. This involves regular echocardiograms to monitor the tumour for any changes in size or mobility.

In such cases, doctors may prescribe anticoagulants (blood thinners) to reduce the risk of clots forming on the surface of the tumour [1] [3]. However, it is vital to understand that anticoagulation does not dissolve the tumour itself, nor does it prevent a piece of the actual tumour tissue from breaking off. Surgery remains the only curative treatment [1] [5].

Surgical Options: The Shift Towards Minimally Invasive Techniques

The primary objective of surgery for a papillary fibroelastoma is the complete excision of the tumour while preserving the patient’s native heart valve [1] [5]. Because these tumours are typically attached by a small stalk, a skilled surgeon can usually shave the tumour off the valve leaflet with precision, leaving the valve intact and fully functional [1]. Valve replacement is rarely necessary unless the valve was already severely diseased prior to the tumour’s development.

Historically, all cardiac surgery was performed via a median sternotomy – the traditional “open-heart” approach. Today, however, advances in surgical technology have made minimally invasive keyhole heart surgery the preferred option for many patients requiring tumour excision.

Traditional Open-Heart Surgery (Median Sternotomy)

In a traditional median sternotomy, the surgeon makes a large incision (typically 20 to 30 centimetres long) down the centre of the chest and divides the breastbone (sternum) to access the heart [6]. The patient is placed on a cardiopulmonary bypass machine (heart-lung machine), which takes over the function of the heart and lungs, allowing the surgeon to open the heart and remove the tumour in a bloodless, motionless field [1].

While this approach provides excellent exposure and is highly safe and effective, it involves significant surgical trauma. The division of the breastbone means that recovery is lengthy. Patients typically spend 5 to 7 days in the hospital and require 3 to 4 months for the sternum to fully heal [6]. During this time, patients experience considerable discomfort and are restricted from heavy lifting, driving, and strenuous physical activity.

Minimally Invasive Keyhole Heart Surgery

As a consultant cardiac surgeon, I strongly advocate for minimally invasive keyhole surgery whenever clinically appropriate. This modern approach achieves the exact same internal result—complete removal of the tumour and preservation of the valve—but through vastly smaller incisions, resulting in significantly less trauma to the patient’s body [6].

In keyhole surgery, the breastbone is not divided. Instead, the surgeon accesses the heart through a small incision (often just 5 to 7 centimetres long) made between the ribs on the right side of the chest [6]. Specialized, elongated surgical instruments and high-definition 3D endoscopic cameras are inserted through this small opening. The camera projects a magnified, brightly illuminated view of the heart valves onto monitors in the operating theatre, allowing the surgeon to perform the delicate excision with exceptional precision [6].

Like traditional surgery, keyhole procedures still require the use of a heart-lung machine to safely stop the heart while the tumour is removed. However, the avoidance of a sternotomy offers profound benefits for the patient.

The Benefits of Keyhole Heart Surgery

The advantages of the keyhole approach over traditional open-heart surgery are substantial and well-documented:

• Dramatically Faster Recovery: Because the breastbone is left intact, the structural integrity of the chest is preserved. This reduces the overall recovery time from 3-4 months down to just 3-4 weeks [6]. Patients can return to their normal daily activities, including driving and working, much sooner.
• Reduced Pain and Discomfort: The smaller incision and the preservation of the sternum result in significantly less postoperative pain. Patients require fewer strong painkillers and experience less discomfort when breathing or coughing [6].
• Shorter Hospital Stay: Patients undergoing keyhole surgery typically spend only 2 to 4 days in the hospital, compared to a week or more for open-heart surgery [6].
• Lower Risk of Complications: Smaller incisions are associated with a reduced risk of surgical site infections and less intraoperative bleeding, which decreases the likelihood of needing a blood transfusion [6].
• Superior Cosmetic Result: The small scar from keyhole surgery is often hidden beneath the breast or in the natural folds of the chest, providing a much more cosmetically appealing outcome than the prominent vertical scar of a sternotomy.

Conclusion

A diagnosis of a papillary fibroelastoma can be daunting, but it is a highly treatable condition. While these benign tumours pose a significant risk of embolic complications such as stroke, timely surgical intervention offers a definitive cure.

The goal of treatment is always to safely remove the tumour while preserving your native heart valve. Today, patients no longer have to endure the lengthy and painful recovery associated with traditional open-heart surgery. Minimally invasive keyhole heart surgery provides a safe, effective, and vastly superior alternative, allowing patients to return to their normal lives in a matter of weeks rather than months.

If you have been diagnosed with a papillary fibroelastoma, it is essential to consult with a cardiac surgeon who specializes in minimally invasive techniques to discuss the best treatment strategy for your specific case.

References

[1] Devanabanda, A. R., & Lee, L. S. (2023). Papillary Fibroelastoma. In StatPearls. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK549829/fibroelastoma on aortic valve

[2] Cleveland Clinic. (2022). Papillary Fibroelastoma: Symptoms, Causes and Treatment. Available at: https://my.clevelandclinic.org/health/diseases/23559-papillary-fibroelastoma

[3] Tamin, S. S., et al. (2015). Prognostic and Bioepidemiologic Implications of Papillary Fibroelastomas. Journal of the American College of Cardiology, 65(22), 2420-2429.

[4] Raheela, F., et al. (2023). Cardiac papillary fibroelastoma: a rare cause of ST-segment elevation myocardial infarction. Annals of Medicine and Surgery, 85(10), 5120-5123. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10617875/

[5] Anastacio, M. M., et al. (2012). Surgical Experience With Cardiac Papillary Fibroelastoma Over a 15-Year Period. The Annals of Thoracic Surgery, 94(2), 537-541. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4329773/

[6] Guy’s and St Thomas’ Specialist Care. (n.d.). Keyhole heart surgery: Reducing recovery from 3 months to 3 weeks. Available at: https://guysandstthomasspecialistcare.co.uk/news/keyhole-heart-surgery-reducing-recovery/

Latest Articles